531 related articles for article (PubMed ID: 11588406)
1. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Oparil S; Williams D; Chrysant SG; Marbury TC; Neutel J
J Clin Hypertens (Greenwich); 2001; 3(5):283-91, 318. PubMed ID: 11588406
[TBL] [Abstract][Full Text] [Related]
2. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
3. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
4. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Mancia G; Korlipara K; van Rossum P; Villa G; Silvert B
Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Ram CV; Ramaswamy K; Qian C; Biskupiak J; Ryan A; Quah R; Russo PA
J Clin Hypertens (Greenwich); 2011 Nov; 13(11):801-12. PubMed ID: 22051424
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
Lacourcière Y
Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
[TBL] [Abstract][Full Text] [Related]
8. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
[TBL] [Abstract][Full Text] [Related]
9. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Nixon RM; Müller E; Lowy A; Falvey H
Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
[TBL] [Abstract][Full Text] [Related]
10. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
11. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
12. Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Saseen JJ; Ghushchyan V; Kaila S; Allen RR; Nair KV
J Clin Hypertens (Greenwich); 2013 Dec; 15(12):888-92. PubMed ID: 24102728
[TBL] [Abstract][Full Text] [Related]
13. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Giles TD; Oparil S; Silfani TN; Wang A; Walker JF
J Clin Hypertens (Greenwich); 2007 Mar; 9(3):187-95. PubMed ID: 17341994
[TBL] [Abstract][Full Text] [Related]
14. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
16. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours.
Neutel J; Weber M; Pool J; Smith D; Fitzsimmons S; Chiang YT; Gatlin M
Clin Ther; 1997; 19(3):447-58; discussion 367-8. PubMed ID: 9220209
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of two treatment combinations of hypertension in very elderly patients.
Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G
Arch Gerontol Geriatr; 2009; 48(3):401-5. PubMed ID: 18457886
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
[TBL] [Abstract][Full Text] [Related]
19. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
